Active Investor Outreach to Build Company Awareness
QUÉBEC CITY, Jan. 25 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS,
TSX: AEZ) (the "Company") today announced it has engaged The Investor
Relations Group ("IRG"), a fourteen-year-old, award-winning, investor
relations firm based in New York City, to serve as its investor
IRG's investor relations team will target specific portfolio managers
and equity analysts in the global investment community to increase
awareness of Aeterna Zentaris' product pipeline and the status of its
ongoing clinical trials.
"Following our very successful R&D review for investors and analysts
held in New York in December, and the establishment of a bold set of
initiatives for 2011, we have decided to enhance our investor relations
program through the appointment of IRG who will expand our reach to the
investment community," commented Juergen Engel, Ph.D., President and
CEO at Aeterna Zentaris. "We are proud of our progress in the
development of a number of highly promising anti-cancer treatments,
particularly perifosine, which is currently in Phase 3 for colorectal
cancer and multiple myeloma, as well as AEZS-108, which has
successfully completed Phase 2 trials in ovarian and endometrial
cancer, with a pivotal trial in endometrial cancer expected to be
initiated this year. Our lead product in endocrinology, Solorel®, is currently in a Phase 3 trial as an oral diagnostic test for Adult
Growth Hormone Deficiency, and we expect to complete the trial and file
a new drug application over the course of this year. We look forward to
working with IRG in order to update the investment community on our
progress throughout the year."
IRG's investor relations program includes new media and multimedia
initiatives that involve the creation of broadcast-ready corporate
videos, podcasts, and the creation of social networking, video service,
and micro-blogging accounts. The Investor Relations Group was recently
honored with a "Stevie Award" for Investor Relations Program of the
Year and named a finalist in the Best Media Website category from the
2009 American Business Awards.
About The Investor Relations Group, Inc.
The Investor Relations Group, Inc. (IRG) offers a full-service corporate
communications program designed to suit the many unique needs of
Alternative Public Offering (APO) companies. The program utilizes a
proprietary, targeted approach to reach institutional investors,
analysts, and the media-at-large. For further information, please visit
the company's website at www.investorrelationsgroup.com.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company
currently investigating potential treatments for various cancers
including colorectal, ovarian, endometrial cancer and multiple myeloma.
The Company's innovative approach of "personalized medicine" means
tailoring treatments to a patient's specific condition and to unmet
medical needs. Aeterna Zentaris' deep pipeline is drawn from its
proprietary discovery unit providing the Company with constant and
long-term access to state-of-the-art therapeutic options. For more
information please visit www.aezsinc.com.
This press release contains forward-looking statements made pursuant to
the safe harbour provisions of the U.S. Securities Litigation Reform
Act of 1995. Forward-looking statements involve known and unknown risks
and uncertainties that could cause the Company's actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the ability of the Company to take
advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in
economic conditions. Investors should consult the Company's quarterly
and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
forward-looking statements. Investors are cautioned not to rely on
these forward-looking statements. The Company does not undertake to
update these forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained herein to
reflect future results, events or developments, unless required to do
so by a governmental authority or by applicable law.
SOURCE AETERNA ZENTARIS INC.
For further information:
Investor Relations Coordinator
(418) 652-8525 ext. 265
The Investor Relations Group
Erika Moran or Adam Holdsworth